In This Section

Recent Press Releases

December 5, 2016

Transaction provides new royalty and potential milestone revenues, opportunity to reduce cost structure, and continuity of patient access to lomitapide

November 29, 2016

-- Transaction creates strong, diversified rare-disease focused portfolio

-- Novelion Therapeutics completes concurrent financing of approximately $22 million

-- Company to host conference call today at 4:30 p.m. ET

November 17, 2016

CAMBRIDGE, Mass., Nov. 17, 2016  -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that Japan's Ministry of Health, Labor & Welfare (MHLW) has approved pricing of JUXTAPID in Japan. The pricing authorization follows Japanese regulatory approval of Juxtapid for the treatment of homozygous familial hypercholesterolemia (HoFH) on September 28, 2016.